News | November 14, 2022
Aurobindo Pharma Q2 FY23 revenue down 3.4%
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Subscribe To Our Newsletter & Stay Updated
